Integrated ddPCR QuantaLife’s ddPCR technology is now part of Bio-Rad’s Digital Biology Center, signaling opportunity to cross-sell Bio-Rad’s scale-up and downstream applications to existing customers and leverage shared sales channels.

Expansion potential Financials indicate Bio-Rad-level growth and ongoing kit launches and Vericheck Kits development, suggesting momentum in validated kits for QC workflows and cell and gene therapy—a pathway to upsell ddPCR-enabled QC solutions to biopharma and contract manufacturers.

Tech ecosystem Existing tech stack (HubSpot, Tableau, CI/CD, cloud tools, AI assistants) points to a modern sales and data analytics environment; leverage analytics and automation to target customers, track ddPCR adoption, and optimize cross-sell campaigns.

Market alignment Recent Bio-Rad product launches in downstream chromatography, Nuvia resins, and process-scale solutions align with CROs, biopharma, and manufacturing partners seeking end-to-end workflows—presenting opportunities to bundle ddPCR with analytics and purification solutions.

Strategic partnerships QuantaLife’s niche in CNV, mutation detection, and gene expression analysis complements Bio-Rad’s broader portfolio; target strategic customers in inherited disorders, cancer, and infectious disease for integrated diagnostic and research workflows.